untitled
<OAI-PMH schemaLocation=http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd>
<responseDate>2018-01-15T18:33:08Z</responseDate>
<request identifier=oai:HAL:hal-00875222v1 verb=GetRecord metadataPrefix=oai_dc>http://api.archives-ouvertes.fr/oai/hal/</request>
<GetRecord>
<record>
<header>
<identifier>oai:HAL:hal-00875222v1</identifier>
<datestamp>2018-01-10</datestamp>
<setSpec>type:ART</setSpec>
<setSpec>subject:sdv</setSpec>
<setSpec>collection:UNIV-PARIS5</setSpec>
<setSpec>collection:UNIV-PARIS7</setSpec>
<setSpec>collection:UPMC</setSpec>
<setSpec>collection:UNIV-AG</setSpec>
<setSpec>collection:IFR140</setSpec>
<setSpec>collection:U938</setSpec>
<setSpec>collection:UNIV-AMU</setSpec>
<setSpec>collection:IRSET</setSpec>
<setSpec>collection:UNIV-RENNES1</setSpec>
<setSpec>collection:APHP</setSpec>
<setSpec>collection:IRSET-HIAEC</setSpec>
<setSpec>collection:BIOSIT</setSpec>
<setSpec>collection:UR1-UFR-SVE</setSpec>
<setSpec>collection:USPC</setSpec>
<setSpec>collection:UR1-HAL</setSpec>
<setSpec>collection:EHESP</setSpec>
<setSpec>collection:STATS-UR1</setSpec>
<setSpec>collection:UR1-SDV</setSpec>
<setSpec>collection:IRSET-2</setSpec>
<setSpec>collection:UNIV-ANGERS</setSpec>
<setSpec>collection:UPMC_POLE_4</setSpec>
</header>
<metadata><dc>
<publisher>HAL CCSD</publisher>
<title lang=en>Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment.</title>
<creator>Capeau, Jacqueline</creator>
<creator>Bouteloup, Vincent</creator>
<creator>Katlama, Christine</creator>
<creator>Bastard, Jean-Philippe</creator>
<creator>Guiyedi, Vincent</creator>
<creator>Salmon-Ceron, Dominique</creator>
<creator>Protopopescu, Camelia</creator>
<creator>Leport, Catherine</creator>
<creator>Raffi, Francois</creator>
<creator>Chêne, Geneviève</creator>
<creator>Michelet, Christian</creator>
<contributor>Centre de Recherche Saint-Antoine (CR Saint-Antoine) ; Université Pierre et Marie Curie - Paris 6 (UPMC) - Institut National de la Santé et de la Recherche Médicale (INSERM)</contributor>
<contributor>Epidémiologie et Biostatistique [Bordeaux] ; Université Bordeaux Segalen - Bordeaux 2 - Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED) - Institut National de la Santé et de la Recherche Médicale (INSERM)</contributor>
<contributor>Epidémiologie, stratégies thérapeutiques et virologie cliniques dans l'infection à VIH ; Université Pierre et Marie Curie - Paris 6 (UPMC) - Institut National de la Santé et de la Recherche Médicale (INSERM)</contributor>
<contributor>Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques ; Université Paris Diderot - Paris 7 (UPD7) - Institut National de la Santé et de la Recherche Médicale (INSERM)</contributor>
<contributor>Service de médecine interne et centre de référence des maladies rares [CHU Cochin] ; Assistance publique - Hôpitaux de Paris (AP-HP) - CHU Cochin [AP-HP]</contributor>
<contributor>Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM) ; Institut de Recherche pour le Développement (IRD) - Aix Marseille Université (AMU) - ORS PACA - Institut National de la Santé et de la Recherche Médicale (INSERM)</contributor>
<contributor>Maladies infectieuses et tropicales</contributor>
<contributor>Institut de recherche, santé, environnement et travail [Rennes] (Irset) ; Université d'Angers (UA) - Université des Antilles et de la Guyane (UAG) - Université de Rennes 1 (UR1) - École des Hautes Études en Santé Publique [EHESP] (EHESP) - Institut National de la Santé et de la Recherche Médicale (INSERM) - Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )</contributor>
<contributor>Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS); Inserm; Collège des Universitaires de Maladies Infectieuses et Tropicales (CMIT ex APPIT); Sidaction Ensemble contre le Sida; associated pharmaceutical companies: Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Gilead Sciences, Pfizer and Roche.</contributor>
<description>International audience</description>
<source>ISSN: 0269-9370</source>
<source>AIDS</source>
<publisher>Lippincott, Williams & Wilkins</publisher>
<identifier>hal-00875222</identifier>
<identifier>https://hal.archives-ouvertes.fr/hal-00875222</identifier>
<source>https://hal.archives-ouvertes.fr/hal-00875222</source>
<source>AIDS, Lippincott, Williams & Wilkins, 2012, 26 (3), pp.303-14. 〈10.1097/QAD.0b013e32834e8776〉</source>
<identifier>DOI : 10.1097/QAD.0b013e32834e8776</identifier>
<relation>info:eu-repo/semantics/altIdentifier/doi/10.1097/QAD.0b013e32834e8776</relation>
<identifier>PUBMED : 22089377</identifier>
<relation>info:eu-repo/semantics/altIdentifier/pmid/22089377</relation>
<language>en</language>
<subject lang=en>diabetes mellitus</subject>
<subject lang=en>HIV infections</subject>
<subject lang=en>indinavir</subject>
<subject lang=en>lipodystrophy</subject>
<subject lang=en>stavudine</subject>
<subject>[SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology</subject>
<type>info:eu-repo/semantics/article</type>
<type>Journal articles</type>
<description lang=en>OBJECTIVE: To evaluate the incidence and determinants of diabetes in a cohort of HIV-infected adults initiated with combination antiretroviral treatment (cART) in 1997-1999 and followed up to 2009. DESIGN: Prospective study of 1046 patients at 47 French clinical sites. METHODS: Potential determinants of diabetes occurrence, defined by confirmed increased glycemia and/or initiation of antidiabetic treatment, were assessed by a proportional hazards model, including time-updated metabolic parameters and ART exposure. RESULTS: Among the cohort, representing 7846 person-years of follow-up (PYFU), 54% received indinavir, 75% stavudine and 52% didanosine. Overall, 111 patients developed diabetes, with an incidence of 14.1/1000 PYFU (14.6 in men, 12.6 in women). Incidence peaked in 1999-2000 (23.2/1000 PYFU) and decreased thereafter. The incidence of diabetes was associated [adjusted hazard ratio (aHR), all P<0.02] with older age (hazard ratio = 2.13 when 40-49 years, hazard ratio = 3.63 when ≥50 years), overweight (hazard ratio = 1.91 for a BMI 25-29 kg/m(2), hazard ratio = 2.85 >30 kg/m(2)), waist-to-hip ratio (hazard ratio = 3.87 for ≥0.97 male/0.92 female), time-updated lipoatrophy (hazard ratio = 2.14) and short-term exposure to indinavir (0-1 year: hazard ratio = 2.53), stavudine (0-1 year: hazard ratio = 2.56, 1-2 years: hazard ratio = 2.65) or didanosine (2-3 years: hazard ratio = 3.16). Occurrence of diabetes was not associated with HIV-related markers, hepatitis C, hypertension or family history of diabetes. Insulin resistance was predictive for incident diabetes. CONCLUSIONS: In this nationwide cohort, followed for 10 years after cART initiation, diabetes incidence peaked in 1990-2000, was markedly higher than that reported for European uninfected or other HIV-infected populations (4-6/1000 PYFU) and linked with age and adiposity. Adiposity and glycemic markers should be monitored in aging HIV-infected patients.</description>
<contributor>ANRS CO8 APROCO-COPILOTE Cohort Study Group</contributor>
<date>2012-01-28</date>
</dc>
</metadata>
</record>
</GetRecord>
</OAI-PMH>
